Investigational Drug Details
| Drug ID: | D472 |
| Drug Name: | Deferiprone |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB08826 |
| DrugBank Description: | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011. |
| PubChem ID: | 2972 |
| CasNo: | 30652-11-0 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CN1C=CC(=O)C(O)=C1C |
| Structure: |
|
| InChiKey: | TZXKOCQBRNJULO-UHFFFAOYSA-N |
| Molecular Weight: | 139.1519 |
| DrugBank Targets: | Iron |
| DrugBank MoA: | Deferiprone is an iron chelator that binds to ferric ions (iron III) and forms a 3:1 (deferiprone:iron) stable complex and is then eliminated in the urine. Deferiprone is more selective for iron in which other metals such as zinc, copper, and aluminum have a lower affinity for deferiprone. |
| DrugBank Pharmacology: | |
| DrugBank Indication: | Deferiprone is indicated in thalassemia syndromes when first line chelation agents are not adequate to treat transfusional iron overload. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L3142 | NCT04726657 | COMPLETED | NO | 2016-01-18 | 2021-01-27 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|